Fu et al. reported that in cytogenetically normal acute myeloid leukemia (CN-AML), a higher level of RUNX1 expression is associated with poorer prognosis, patients with high expression values showed a shorter overall survival (OS) and a shorter symptom-free survival (EFS) [33]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.